Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone [Yahoo! Finance]
Psyence Biomedical Ltd. - Common Shares (PBM)
Company Research
Source: Yahoo! Finance
NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) today reinforced how its strategic investment in PsyLabs strengthens its control over pharmaceutical-grade manufacturing and commercial supply chain infrastructure – a critical differentiator in the rapidly expanding psychedelic pharmaceutical sector. Through its investment in PsyLabs, Psyence BioMed has secured: A licensed, owned, and debt-free production operation. Source-level ibogaine supply. Natural psilocybin supply. GMP-compliant manufacturing capabilities. Intellectual property protection. Integrated analytical and chemistry laboratory infrastructure. A capital structure with no corporate debt. As the psychedelic therapeutics sector matures, scalable pharmaceutical-grade manufacturing has become one of the most significant barriers to entry. PsyLabs operates fully compliant production and laboratory facilities capable of supplying pharmaceut
Show less
Read more
Impact Snapshot
Event Time:
PBM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PBM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PBM alerts
High impacting Psyence Biomedical Ltd. - Common Shares news events
Weekly update
A roundup of the hottest topics
PBM
News
- Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export MilestoneGlobeNewswire
- Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical TrialGlobeNewswire
- Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity InvestmentGlobeNewswire
- Psyence BioMed Announces Results of Annual and Special Meeting of ShareholdersGlobeNewswire
- Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization PathwayGlobeNewswire
PBM
Sec Filings
- 3/2/26 - Form 6-K
- 2/20/26 - Form 6-K
- 2/19/26 - Form SCHEDULE
- PBM's page on the SEC website